Nextgen Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.80 M
as on 16-11-2024
- Revenue -42.86%
(FY 2023)
- Profit -71.77%
(FY 2023)
- Ebitda -64.14%
(FY 2023)
- Net Worth 12.13%
(FY 2023)
- Total Assets -1.40%
(FY 2023)
About Nextgen Life Sciences
The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.80 M.
Nagma Abbasi and Sajid Ali serve as directors at the Company.
- CIN/LLPIN
U52100DL2014PTC268147
- Company No.
268147
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jun 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Nextgen Life Sciences Private Limited offer?
Nextgen Life Sciences Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Corona Test Kit, Rapid Test Kit, Plastic & Glass Labware, Volumetric Pipette, PCR Machine, Laboratory Plasticware, Surgical & ICU Equipments, Medical Equipment & Accessories.
Who are the key members and board of directors at Nextgen Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nagma Abbasi  | Director | 21-Jun-2014 | Current |
| Sajid Ali | Director | 21-Jun-2014 | Current |
Financial Performance of Nextgen Life Sciences.
Nextgen Life Sciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 42.86% decrease. The company also saw a substantial fall in profitability, with a 71.77% decrease in profit. The company's net worth Soared by an impressive increase of 12.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nextgen Life Sciences?
In 2023, Nextgen Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 28 Sep 2021 | ₹1.80 M | Open |
How Many Employees Work at Nextgen Life Sciences?
Unlock and access historical data on people associated with Nextgen Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nextgen Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nextgen Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
